High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins

Archives of Toxicology

Volumn 89, Issue 10, 2015, Pages 1847-1860

  Tolosa, Laia ^a   Carmona, Antonio ^a   Castell, José V ^a,b,c   Gómez Lechón, M José ^a,c   Donato, M Teresa ^a,b,c  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Hepatotoxicity; High content screening; Mitochondrial injury; Statins

Indexed keywords

CALCIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SUPEROXIDE;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL VIABILITY; HEPG2 CELL LINE; HUMAN; IN VITRO STUDY; LIVER MITOCHONDRION; LIVER TOXICITY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MITOCHONDRIAL TOXICITY; PRIORITY JOURNAL; RISK ASSESSMENT; TOXIC HEPATITIS; TOXICITY ASSAY; CELL SURVIVAL; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; LIVER CELL; METABOLISM; PATHOLOGY;

APOPTOSIS; CALCIUM; CELL SURVIVAL; DRUG-INDUCED LIVER INJURY; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA, LIVER;

EID: 84942117086     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1334-3     Document Type: Article

References (67)

1. Abboud G, Kaplowitz N (2007) Drug-induced liver injury. Drug Saf 30(4):277–294
2. Abdoli N, Heidari R, Azarmi Y, Eghbal MA (2013) Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes. J Biochem Mol Toxicol 27(6):287–294. doi:10.1002/jbt.21485
3. Amacher DE (2005) Drug-associated mitochondrial toxicity and its detection. Curr Med Chem 12(16):1829–1839
4. Apostolova N, Gomez-Sucerquia LJ, Moran A, Alvarez A, Blas-Garcia A, Esplugues JV (2010) Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. Br J Pharmacol 160(8):2069–2084. doi:10.1111/j.1476-5381.2010.00866.x
5. Beeson CC, Beeson GC, Schnellmann RG (2010) A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Anal Biochem 404(1):75–81. doi:10.1016/j.ab.2010.04.040
6. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B (2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 54(4):773–794. doi:10.1016/j.jhep.2010.11.006
7. Bellosta S, Paoletti R, Corsini A (2004) Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(23 Suppl 1):III50–III57. doi:10.1161/01.CIR.0000131519.15067.1f
8. Beltowski J, Wojcicka G, Jamroz-Wisniewska A (2009) Adverse effects of statins—mechanisms and consequences. Curr Drug Saf 4(3):209–228
9. Bergmann OM, Kristjansson G, Jonasson JG, Bjornsson ES (2012) Jaundice due to suspected statin hepatotoxicity: a case series. Dig Dis Sci 57(7):1959–1964. doi:10.1007/s10620-011-1950-1
10. Bhardwaj SS, Chalasani N (2007) Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 11(3):597–613, vii. doi:10.1016/j.cld.2007.06.010
11. Bjornsson E, Jacobsen EI, Kalaitzakis E (2012) Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol 56(2):374–380. doi:10.1016/j.jhep.2011.07.023
12. Braun JS, Geiger R, Wehner H, Schaffer S, Berger M (1998) Hepatitis caused by antidepressive therapy with maprotiline and opipramol. Pharmacopsychiatry 31(4):152–155. doi:10.1055/s-2007-979319
13. Brien JF, Jimmo S, Brennan FJ, Ford SE, Armstrong PW (1987) Distribution of amiodarone and its metabolite, desethylamiodarone, in human tissues. Can J Physiol Pharmacol 65(3):360–364
14. Cosgrove BD, King BM, Hasan MA, Alexopoulos LG, Farazi PA, Hendriks BS, Griffith LG, Sorger PK, Tidor B, Xu JJ, Lauffenburger DA (2009) Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 237(3):317–330. doi:10.1016/j.taap.2009.04.002
15. Costa RA, Fernandes MP, de Souza-Pinto NC, Vercesi AE (2013) Protective effects of l-carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin. Eur J Pharmacol 701(1–3):82–86. doi:10.1016/j.ejphar.2013.01.001
16. Cottet-Rousselle C, Ronot X, Leverve X, Mayol JF (2011) Cytometric assessment of mitochondria using fluorescent probes. Cytometry A 79(6):405–425. doi:10.1002/cyto.a.21061
17. De la Iglesia Inigo S, Lopez-Jorge CE, Gomez-Casares MT, Castellano AL, Cabrera PM, Brito JL, Cabrera AS, Labarta TM (2009) Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents. Leuk Res 33(6):810–816. doi:10.1016/j.leukres.2008.09.029
18. Dong Z, Saikumar P, Weinberg JM, Venkatachalam MA (2006) Calcium in cell injury and death. Annu Rev Pathol 1:405–434. doi:10.1146/annurev.pathol.1.110304.100218
19. Dykens JA, Will Y (2007) The significance of mitochondrial toxicity testing in drug development. Drug Discov Today 12(17–18):777–785. doi:10.1016/j.drudis.2007.07.013
20. Dykens JA, Marroquin LD, Will Y (2007) Strategies to reduce late-stage drug attrition due to mitochondrial toxicity. Expert Rev Mol Diagn 7(2):161–175. doi:10.1586/14737159.7.2.161
21. Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, Smith AR, Will Y (2008) In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 103(2):335–345. doi:10.1093/toxsci/kfn056
22. Furberg CD, Pitt B (2001) Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2(5):205–207
23. Golomb BA, Evans MA (2008) Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 8(6):373–418
24. Gomez-Lechon MJ, O’Connor E, Castell JV, Jover R (2002) Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes. Toxicol Sci 65(2):299–308
25. Gustafsson F, Foster AJ, Sarda S, Bridgland-Taylor MH, Kenna JG (2014) A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. Toxicol Sci 137(1):189–211. doi:10.1093/toxsci/kft223
26. Hellebrand EE, Varbiro G (2010) Development of mitochondrial permeability transition inhibitory agents: a novel drug target. Drug Discov Ther 4(2):54–61
27. Holme AL, Yadav SK, Pervaiz S (2007) Automated laser scanning cytometry: a powerful tool for multi-parameter analysis of drug-induced apoptosis. Cytometry A 71(2):80–86. doi:10.1002/cyto.a.20362
28. Hynes J, Nadanaciva S, Swiss R, Carey C, Kirwan S, Will Y (2013) A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. Toxicol In Vitro 27(2):560–569. doi:10.1016/j.tiv.2012.11.002
29. Kah J, Wustenberg A, Keller AD, Sirma H, Montalbano R, Ocker M, Volz T, Dandri M, Tiegs G, Sass G (2012) Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep 28(3):1077–1083. doi:10.3892/or.2012.1860
30. Kim JA, Han E, Eun CJ, Tak YK, Song JM (2012) Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity. Toxicol Lett 214(2):175–181. doi:10.1016/j.toxlet.2012.08.027
31. Labbe G, Pessayre D, Fromenty B (2008) Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol 22(4):335–353. doi:10.1111/j.1472-8206.2008.00608.x
32. Lee WM (2003) Drug-induced hepatotoxicity. N Engl J Med 349(5):474–485
33. Maeda A, Yano T, Itoh Y, Kakumori M, Kubota T, Egashira N, Oishi R (2010) Down-regulation of RhoA is involved in the cytotoxic action of lipophilic statins in HepG2 cells. Atherosclerosis 208(1):112–118. doi:10.1016/j.atherosclerosis.2009.07.033
34. Martin EA, Carthew P, White IN, Heydon RT, Gaskell M, Mauthe RJ, Turteltaub KW, Smith LL (1997) Investigation of the formation and accumulation of liver DNA adducts in mice chronically exposed to tamoxifen. Carcinogenesis 18(11):2209–2215
35. McBride HM, Neuspiel M, Wasiak S (2006) Mitochondria: more than just a powerhouse. Curr Biol 16(14):R551–R560. doi:10.1016/j.cub.2006.06.054
36. Mitchell DB, Acosta D (1981) Evaluation of the cytotoxicity of tricyclic antidepressants in primary cultures of rat hepatocytes. J Toxicol Environ Health 7(1):83–92. doi:10.1080/15287398109529960
37. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y (2007) Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 223(3):277–287. doi:10.1016/j.taap.2007.06.003
38. Neustadt J, Pieczenik SR (2008) Medication-induced mitochondrial damage and disease. Mol Nutr Food Res 52(7):780–788. doi:10.1002/mnfr.200700075
39. Noor F, Niklas J, Muller-Vieira U, Heinzle E (2009) An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells. Toxicol Appl Pharmacol 237(2):221–231. doi:10.1016/j.taap.2009.03.011
40. O’Brien PJ, Irwin W, Diaz D, Howard-Cofield E, Krejsa CM, Slaughter MR, Gao B, Kaludercic N, Angeline A, Bernardi P, Brain P, Hougham C (2006) High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80(9):580–604. doi:10.1007/s00204-006-0091-3
41. Ohtsu T, Sasaki Y, Igarashi T, Murayama T, Kobayashi Y, Tobinai K (1998) Unexpected hepatotoxicities in patients with non-Hodgkin’s lymphoma treated with irinotecan (CPT-11) and etoposide. Jpn J Clin Oncol 28(8):502–506
42. Paine SW, Parker AJ, Gardiner P, Webborn PJ, Riley RJ (2008) Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 36(7):1365–1374. doi:10.1124/dmd.107.019455
43. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP (2005a) The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45:177–202
44. Park K, Williams DP, Naisbitt DJ, Kitteringham NR, Pirmohamed M (2005b) Investigation of toxic metabolites during drug development. Toxicol Appl Pharmacol 207(2 Suppl):425–434
45. Pereira CV, Moreira AC, Pereira SP, Machado NG, Carvalho FS, Sardao VA, Oliveira PJ (2009) Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety? Curr Drug Saf 4(1):34–54
46. Pessayre D, Mansouri A, Berson A, Fromenty B (2010) Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol 196:311–365. doi:10.1007/978-3-642-00663-0_11
47. Pessayre D, Fromenty B, Berson A, Robin MA, Letteron P, Moreau R, Mansouri A (2012) Central role of mitochondria in drug-induced liver injury. Drug Metab Rev 44(1):34–87. doi:10.3109/03602532.2011.604086
48. Petronilli V, Miotto G, Canton M, Brini M, Colonna R, Bernardi P, Di Lisa F (1999) Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J 76(2):725–734. doi:10.1016/S0006-3495(99)77239-5
49. Porceddu M, Buron N, Roussel C, Labbe G, Fromenty B, Borgne-Sanchez A (2012) Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria. Toxicol Sci. doi:10.1093/toxsci/KFS197
50. Presley AD, Fuller KM, Arriaga EA (2003) MitoTracker Green labeling of mitochondrial proteins and their subsequent analysis by capillary electrophoresis with laser-induced fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 793(1):141–150
51. Raza H, John A (2012) Implications of altered glutathione metabolism in aspirin-induced oxidative stress and mitochondrial dysfunction in HepG2 cells. PLoS ONE 7(4):e36325. doi:10.1371/journal.pone.0036325
52. Russmann S, Kullak-Ublick GA, Grattagliano I (2009) Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 16(23):3041–3053
53. Russo MW, Scobey M, Bonkovsky HL (2009) Drug-induced liver injury associated with statins. Semin Liver Dis 29(4):412–422. doi:10.1055/s-0029-1240010
54. Schoonen WG, de Roos JA, Westerink WM, Debiton E (2005a) Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1 and CHO cells. II mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol In Vitro 19(4):491–503. doi:10.1016/j.tiv.2005.01.002
55. Schoonen WG, Westerink WM, de Roos JA, Debiton E (2005b) Cytotoxic effects of 100 reference compounds on Hep G2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I mechanistic assays on ROS, glutathione depletion and calcein uptake. Toxicol In Vitro 19(4):505–516. doi:10.1016/j.tiv.2005.01.003
56. Sirvent P, Mercier J, Lacampagne A (2008) New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol 8(3):333–338. doi:10.1016/j.coph.2007.12.010
57. Tait SW, Green DR (2012) Mitochondria and cell signalling. J Cell Sci 125(Pt 4):807–815
58. Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, Swallow S, Middleton B, Stahl S, Foster AJ, Dolgos H, Weaver R, Kenna JG (2012) In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 25(8):1616–1632. doi:10.1021/tx300091x
59. Tolosa L, Pinto S, Donato MT, Lahoz A, Castell JV, O’Connor JE, Gomez-Lechon MJ (2012) Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol Sci 127(1):187–198. doi:10.1093/toxsci/kfs083
60. Tolosa L, Gomez-Lechon MJ, Perez-Cataldo G, Castell JV, Donato MT (2013) HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved. Arch Toxicol 87(6):1115–1127. doi:10.1007/s00204-013-1012-x
61. Tsiper MV, Sturgis J, Avramova LV, Parakh S, Fatig R, Juan-Garcia A, Li N, Rajwa B, Narayanan P, Qualls CW Jr, Robinson JP, Davisson VJ (2012) Differential mitochondrial toxicity screening and multi-parametric data analysis. PLoS ONE 7(10):e45226. doi:10.1371/journal.pone.0045226
62. Van Summeren A, Renes J, Bouwman FG, Noben JP, van Delft JH, Kleinjans JC, Mariman EC (2011) Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci 120(1):109–122. doi:10.1093/toxsci/kfq380
63. Vignati L, Turlizzi E, Monaci S, Grossi P, Kanter R, Monshouwer M (2005) An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216(2–3):154–167. doi:10.1016/j.tox.2005.08.003
64. Walgren JL, Mitchell MD, Thompson DC (2005) Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 35(4):325–361
65. Wlodkowic D, Skommer J, Hillier C, Darzynkiewicz Z (2008) Multiparameter detection of apoptosis using red-excitable SYTO probes. Cytometry A 73(6):563–569. doi:10.1002/cyto.a.20564
66. Wlodkowic D, Faley S, Darzynkiewicz Z, Cooper JM (2011) Real-time cytotoxicity assays. Methods Mol Biol 731:285–291. doi:10.1007/978-1-61779-080-5_23
67. Xu JJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105(1):97–105. doi:10.1093/toxsci/kfn109